Qualitative structure-metabolism relationships in the hydrolysis of carbamates

被引:61
作者
Vacondio, Federica [1 ]
Silva, Claudia [1 ]
Mor, Marco [1 ]
Testa, Bernard [2 ]
机构
[1] Univ Parma, Dipartimento Farmaceut, I-43100 Parma, Italy
[2] Univ Hosp Ctr CHUV, Dept Pharm, Lausanne, Switzerland
关键词
Carbamates; structure-property relationships (SPR); hydrolysis; metabolic stability; drug metabolism; IN-VITRO METABOLISM; HIV-1 PROTEASE INHIBITOR; HUMAN-LIVER-MICROSOMES; C-14 N-ETHOXYCARBONYL-3-MORPHOLINOSYDNONIMINE MOLSIDOMINE; LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY; REVERSE-TRANSCRIPTASE INHIBITOR; ORAL FLUOROPYRIMIDINE CARBAMATE; MECHANISM-BASED INACTIVATION; HUMAN MORICIZINE METABOLISM; NUCLEAR-MAGNETIC-RESONANCE;
D O I
10.3109/03602531003745960
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aims of this review were 1) to compile a large number of reliable literature data on the metabolic hydrolysis of medicinal carbamates and 2) to extract from such data a qualitative relation between molecular structure and lability to metabolic hydrolysis. The compounds were classified according to the nature of their substituents ((ROCONRR2)-O-3-R-1), and a metabolic lability score was calculated for each class. A trend emerged, such that the metabolic lability of carbamates decreased (i.e., their metabolic stability increased), in the following series: Aryl-OCO-NHAlkyl >> Alkyl-OCO-NHAlkyl similar to Alkyl-OCO-N(Alkyl)(2) >= Alkyl-OCO-N(endocyclic) >= Aryl-OCO-N(Alkyl)(2) similar to Aryl-OCO-N(endocyclic) >= Alkyl-OCO-NHAryl similar to Alkyl-OCO-NHAcyl >> Alkyl-OCO-NH2 > Cyclic carbamates. This trend should prove useful in the design of carbamates as drugs or prodrugs.
引用
收藏
页码:551 / 589
页数:39
相关论文
共 262 条
[1]  
ADUSUMALLI VE, 1991, DRUG METAB DISPOS, V19, P1135
[2]  
ADUSUMALLI VE, 1993, DRUG METAB DISPOS, V21, P710
[3]   (ACYLOXY)ALKYL CARBAMATE PRODRUGS OF NORFLOXACIN [J].
ALEXANDER, J ;
FROMTLING, RA ;
BLAND, JA ;
PELAK, BA ;
GILFILLAN, EC .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (01) :78-81
[4]   Investigation of (oxodioxolenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral amines [J].
Alexander, J ;
Bindra, DS ;
Glass, JD ;
Holahan, MA ;
Renyer, ML ;
Rork, GS ;
Sitko, GR ;
Stranieri, MT ;
Stupienski, RF ;
Veerapanane, H ;
Cook, JJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (02) :480-486
[5]   THE METABOLIC AND PHARMACOKINETIC DISPOSITION OF MEBENDAZOLE IN THE RAT [J].
ALLAN, RJ ;
WATSON, TR .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1983, 8 (04) :373-381
[6]   IDENTIFICATION OF BILIARY METABOLITES OF MEBENDAZOLE IN THE RAT [J].
ALLAN, RJ ;
WATSON, TR .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1982, 7 (02) :131-136
[7]  
AMRI HS, 1988, J PHARMACOL EXP THER, V246, P758
[8]   DESIGN, SYNTHESIS, ANTINEOPLASTIC ACTIVITY, AND CHEMICAL-PROPERTIES OF BIS(CARBAMATE) DERIVATIVES OF 4,5-BIS(HYDROXYMETHYL)IMIDAZOLE [J].
ANDERSON, WK ;
BHATTACHARJEE, D ;
HOUSTON, DM .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (01) :119-127
[9]  
ANDERSSON S B, 1981, European Journal of Drug Metabolism and Pharmacokinetics, V6, P149
[10]  
[Anonymous], 2003, HYDROLYSIS DRUG PROD